Design, synthesis, and biological evaluation of new 2-(4-(methylsulfonyl)phenyl)-N-phenylimidazo[1,2-a]pyridin-3-amine as selective COX-2 inhibitors
Authors:
Preprint
- 6 December 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Cyclooxygenase (COX), which plays a role in converting arachidonic acid to inflammatory mediators, could be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs). Although potent NSAIDs are available for the treatment of pain, fever, and inflammation, some side effects such as gastrointestinal ulcers limit the use of these medications. During recent years, selective COX-2 inhibitors with a lower incidence of adverse effects attained an important position in medicinal chemistry. In order to introduce some new potent COX-2 inhibitors, a new series of 2-(4-(methylsulfonyl)phenyl)-N-phenylimidazo[1,2-a]pyridin-3-amines was designed, synthesized, and evaluated. The designed compounds were synthesized through multistep reactions. Enzyme inhibition assay and formalin test were performed to evaluate the activity of these compounds. The docking studies demonstrated SO2Me pharmacophore was inserted into the secondary pocket of COX-2, and other parts of docked molecules were positioned as well as a crystallographic ligand in the COX-2 active site. Among these compounds, 8-methyl-2-(4-(methylsulfonyl)phenyl)-N-(p-tolyl)imidazo[1,2-a]pyridin-3-amine (5n) exhibited the most potency and selectivity against COX-2 (IC50= 0.07 µM, SI= 508.6). The antinociceptive activity assessment via the formalin test showed that nine derivatives (5a, 5d, 5h, 5i, 5k, 5q, 5r, 5s, and 5t) possessed significant activity compared with the control group with a p-value less than 0.05.Keywords
All Related Versions
- Version 1, 2022-12-06, Research Square
- Published version: Medicinal Chemistry Research, 32 (5), 856.
This publication has 39 references indexed in Scilit:
- Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzymeEuropean Journal of Medicinal Chemistry, 2012
- Design and Synthesis of New 1,3‐Benzdiazinan‐4‐one Derivatives as Selective Cyclooxygenase (COX‐2) InhibitorsArchiv der Pharmazie, 2011
- Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective Cyclooxygenase-2 InhibitorsScientia Pharmaceutica, 2011
- Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitorsEuropean Journal of Medicinal Chemistry, 2010
- Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitorsBioorganic & Medicinal Chemistry, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analoguesBioorganic & Medicinal Chemistry Letters, 2008
- Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Prostaglandin synthase 2Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and catsPain, 1977